Scarica l'app Stockscreener
1.44
2.13%
0.03
Precedente Chiudi:
$1.41
Aprire:
$1.37
Volume 24 ore:
1.52M
Relative Volume:
0.52
Capitalizzazione di mercato:
$586.50M
Reddito:
$400.57M
Utile/perdita netta:
$9.21M
Rapporto P/E:
36.00
EPS:
0.04
Flusso di cassa netto:
$146.36M
1 W Prestazione:
-1.37%
1M Prestazione:
-10.56%
6M Prestazione:
-66.20%
1 anno Prestazione:
-82.48%
Intervallo 1D:
$1.355
$1.45
Intervallo di 1 settimana:
$1.32
$1.505
Portata 52W:
$1.32
$8.45
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Nome
Ironwood Pharmaceuticals Inc
Settore
Telefono
617-621-7722
Indirizzo
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Confronta IRWD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
1.44 | 586.50M | 400.57M | 9.21M | 146.36M | 0.04 |
|
ZTS
Zoetis Inc
|
163.50 | 72.50B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.98 | 47.08B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.16 | 45.99B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.29 | 17.52B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
312.26 | 13.78B | 2.76B | 1.11B | 898.10M | 22.77 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-09 | Iniziato | Leerink Partners | Market Perform |
| 2024-08-08 | Downgrade | CapitalOne | Overweight → Equal Weight |
| 2024-01-17 | Iniziato | Craig Hallum | Buy |
| 2023-12-14 | Iniziato | Wells Fargo | Overweight |
| 2023-11-09 | Iniziato | Jefferies | Buy |
| 2023-09-28 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-09-02 | Iniziato | CapitalOne | Overweight |
| 2022-04-22 | Iniziato | Piper Sandler | Overweight |
| 2020-09-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-06-17 | Iniziato | Northland Capital | Outperform |
| 2019-07-10 | Ripresa | Credit Suisse | Neutral |
| 2019-03-27 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2019-02-25 | Aggiornamento | H.C. Wainwright | Sell → Neutral |
| 2019-01-24 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2018-11-07 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2018-11-07 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-07-23 | Iniziato | H.C. Wainwright | Sell |
| 2018-05-09 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2018-01-05 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2017-12-06 | Downgrade | Mizuho | Buy → Neutral |
| 2017-07-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2017-05-03 | Iniziato | Wells Fargo | Outperform |
| 2017-04-07 | Reiterato | Mizuho | Buy |
| 2017-02-22 | Reiterato | Barclays | Equal Weight |
| 2016-11-04 | Reiterato | Mizuho | Buy |
| 2016-10-24 | Reiterato | Wedbush | Neutral |
| 2016-10-10 | Reiterato | Mizuho | Buy |
| 2016-09-27 | Reiterato | WallachBeth | Hold |
Mostra tutto
Ironwood Pharmaceuticals Inc Borsa (IRWD) Ultime notizie
Short Bowel Syndrome Market Growth Projections 2024-2034: - openPR.com
IRONWOOD PHARMACEUTICALS INC SEC 10-K Report - TradingView
Ironwood Pharmaceuticals (IRWD) Faces Nasdaq Compliance Deadline - GuruFocus.com
Ironwood Pharmaceuticals Gets Nasdaq Non-Compliance Notice - MarketScreener
Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing - Business Wire
Ironwood Pharma Gets 60-Day Window to Resolve Nasdaq Compliance Issue - Stock Titan
Catalyst (CPRX) Surges 6.2%: Is This an Indication of Further Gains? - Yahoo Finance
Charles Schwab Investment Management Inc. Has $8.79 Million Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Defense World
StockNews.com Downgrades Ironwood Pharmaceuticals (NASDAQ:IRWD) to Hold - Armenian Reporter
Irritable Bowel Syndrome Treatment Market Future Business - openPR.com
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD): Blank Check On Growth? - Stocks Register
Analysts Set Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Price Target at $8.60 - Defense World
Ironwood Pharmaceuticals Inc (IRWD) Q4 2024 Earnings Report Prev - GuruFocus.com
Analysts Say You Should Hold Your Position In Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) - Stocks Register
Ironwood Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Ironwood Pharmaceuticals, Inc. Class A to Host Earnings Call - accessnewswire.com
IRWD's Q4 Earnings and Revenues Fall Shy of Estimates, Stock Down - MSN
Ironwood Pharma Delays 10-K Filing Due to Internal Issues - TipRanks
Is Ironwood Pharmaceuticals, Inc. (IRWD) the Best Small Cap Pharma Stocks to Buy Now? - Insider Monkey
Is Ironwood Pharmaceuticals, Inc. (IRWD) the Best Small Cap Pharma Stock to Buy Now? - Yahoo Finance
Los Angeles Capital Management LLC Boosts Stock Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - MarketBeat
Ironwood Pharmaceuticals (IRWD) Q4 Earnings and Revenues Miss Estimates - MSN
Ironwood Pharmaceuticals (NASDAQ:IRWD) Issues Earnings Results, Misses Estimates By $0.08 EPS - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Releases Quarterly Earnings Results - MarketBeat
12 Best Small Cap Pharma Stocks to Buy Now - Insider Monkey
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q4 2024 Earnings Call Transcript - Insider Monkey
Ironwood: Q4 Earnings Snapshot - The Herald Review
Ironwood Pharmaceuticals Inc (IRWD) Q4 2024 Earnings Call Highlights: Strong Prescription ... - Yahoo Finance
Ironwood Pharmaceuticals Inc (IRWD) Q4 2024 Earnings Call Highlights: Strong Prescription ... By GuruFocus - Investing.com Canada
Ironwood Pharmaceuticals Reports 2024 Financial Results - TipRanks
Investor Network: Ironwood Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Ironwood Pharmaceuticals’ Earnings Call: Growth Amid Challenges - TipRanks
Ironwood Pharmaceuticals chief legal officer sells shares worth $68,530 - MSN
Ironwood Pharma stock surges 9% on apraglutide progress, Linzess growth - Investing.com India
Ironwood Pharma stock surges 9% on apraglutide progress, Linzess growth By Investing.com - Investing.com South Africa
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results - TradingView
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance - Business Wire
CIBC Asset Management Inc Takes $53,000 Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Defense World
Ironwood Pharmaceuticals Inc (IRWD) Q4 2024 Earnings Report Preview: What To Look For - Yahoo Finance
Ironwood Pharmaceuticals Inc expected to post earnings of 8 cents a shareEarnings Preview - TradingView
Brokerages Set Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) PT at $8.60 - Defense World
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call - BioSpace
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Sees Large Growth in Short Interest - MarketBeat
Ironwood Pharmaceuticals Inc (IRWD): A New Perspective - Stocks Register
FY2025 Earnings Forecast for IRWD Issued By Zacks Research - MarketBeat
IRWD Begins Apraglutide NDA Submission, Announces Job Cuts, Stock Falls - MSN
Zacks Research Issues Negative Forecast for IRWD Earnings - MarketBeat
What is Zacks Research’s Estimate for IRWD FY2025 Earnings? - Defense World
Ironwood Pharmaceuticals Inc Azioni (IRWD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.06%
0.52%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):